Table 3.
Selected clinical studies of strategies to prevent progression of MGUS, SMM, and early-stage multiple myeloma
Adapted from Waxman et al.81
IMM indicates indolent multiple myeloma (asymptomatic but with evidence of end-organ damage); MR, minor response (25%-50% decrease in M-protein); PR, partial response (≥50% decrease in M-protein); CR, complete response (no detectable M-protein); MP, melphalan/prednisone; VAD, vincristine, (Adriamycin) now called doxorubicin, dexamethasone; DEX, dexamethasone; TTP, time to progression; and PFS, progression-free survival.
*Estimated enrollment.
